tradingkey.logo

GlucoTrack Inc

GCTK
6.080USD
-0.380-5.88%
Close 11/04, 16:00ETQuotes delayed by 15 min
5.47MMarket Cap
LossP/E TTM

GlucoTrack Inc

6.080
-0.380-5.88%

More Details of GlucoTrack Inc Company

Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.

GlucoTrack Inc Info

Ticker SymbolGCTK
Company nameGlucoTrack Inc
IPO dateApr 09, 2013
CEOMr. Paul V. Goode, Ph.D.
Number of employees11
Security typeOrdinary Share
Fiscal year-endApr 09
Address301 Rt 17 North
CityRUTHERFORD
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code07070
Phone197286757878
Website
Ticker SymbolGCTK
IPO dateApr 09, 2013
CEOMr. Paul V. Goode, Ph.D.

Company Executives of GlucoTrack Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Andrew K. Balo
Mr. Andrew K. Balo
Independent Director
Independent Director
2.65K
+94.49%
Dr. Victoria E. Carr-Brendel, Ph.D.
Dr. Victoria E. Carr-Brendel, Ph.D.
Independent Director
Independent Director
--
--
Ms. Erin Carter
Ms. Erin Carter
Independent Director
Independent Director
--
--
Mr. Luis J. Malave
Mr. Luis J. Malave
Independent Director
Independent Director
--
--
Mr. Paul V. Goode, Ph.D.
Mr. Paul V. Goode, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Peter C. Wulff
Mr. Peter C. Wulff
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Andrew K. Balo
Mr. Andrew K. Balo
Independent Director
Independent Director
2.65K
+94.49%
Dr. Victoria E. Carr-Brendel, Ph.D.
Dr. Victoria E. Carr-Brendel, Ph.D.
Independent Director
Independent Director
--
--
Ms. Erin Carter
Ms. Erin Carter
Independent Director
Independent Director
--
--
Mr. Luis J. Malave
Mr. Luis J. Malave
Independent Director
Independent Director
--
--
Mr. Paul V. Goode, Ph.D.
Mr. Paul V. Goode, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Peter C. Wulff
Mr. Peter C. Wulff
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
--
--

Revenue Breakdown

No Data
No Data
By Business
By Region
No Data

Shareholding Stats

Updated: Sun, Nov 2
Updated: Sun, Nov 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Ballantyne (John)
5.12%
John A Ballantyne Rev Trust
5.08%
BofA Global Research (US)
0.45%
Malave (Luis)
0.37%
Balo (Andrew K)
0.29%
Other
88.68%
Shareholders
Shareholders
Proportion
Ballantyne (John)
5.12%
John A Ballantyne Rev Trust
5.08%
BofA Global Research (US)
0.45%
Malave (Luis)
0.37%
Balo (Andrew K)
0.29%
Other
88.68%
Shareholder Types
Shareholders
Proportion
Individual Investor
6.01%
Corporation
5.13%
Research Firm
0.46%
Hedge Fund
0.20%
Investment Advisor
0.10%
Investment Advisor/Hedge Fund
0.06%
Other
88.05%

Institutional Shareholding

Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
28
7.28K
0.81%
+441.00
2025Q2
33
57.12K
10.07%
+7.03K
2025Q1
39
2.63M
26.00%
+2.61M
2024Q4
34
288.83K
2.77%
+184.21K
2024Q3
32
114.00K
32.14%
+19.53K
2024Q2
25
96.30K
35.98%
+32.90K
2024Q1
25
100.82K
37.68%
+41.48K
2023Q4
20
58.71K
36.83%
-16.43K
2023Q3
19
75.13K
44.69%
+1.11K
2023Q2
16
74.00K
44.15%
+21.12K
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Ballantyne (John)
46.02K
5.12%
+45.95K
+66589.86%
Sep 23, 2025
John A Ballantyne Rev Trust
45.73K
5.08%
+1.00
+0.00%
Sep 23, 2025
BofA Global Research (US)
4.09K
0.45%
+4.09K
--
Jun 30, 2025
Malave (Luis)
2.86K
0.32%
-736.00
-20.48%
Sep 23, 2025
Balo (Andrew K)
1.36K
0.15%
-2.05K
-60.08%
Sep 23, 2025
Tower Research Capital LLC
1.77K
0.2%
+1.77K
--
Jun 30, 2025
Carter (Erin Catherine)
1.15K
0.13%
-613.00
-34.81%
Sep 23, 2025
Barclays Bank PLC
751.00
0.08%
+751.00
--
Jun 30, 2025
Sabby Management, LLC
539.00
0.06%
+539.00
--
Dec 31, 2024
Alma Diversified Holdings LLC
429.00
0.05%
--
--
Sep 05, 2024
View more

Related ETFs

Name
Proportion
No Data

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Split

Date
Type
Ratio
Jan 30, 2025
Merger
20→1
Jan 30, 2025
Merger
20→1
Jan 30, 2025
Merger
20→1
Jan 30, 2025
Merger
20→1
May 15, 2024
Merger
5→1
May 15, 2024
Merger
5→1
Date
Type
Ratio
Jan 30, 2025
Merger
20→1
Jan 30, 2025
Merger
20→1
Jan 30, 2025
Merger
20→1
Jan 30, 2025
Merger
20→1
May 15, 2024
Merger
5→1
May 15, 2024
Merger
5→1
May 15, 2024
Merger
5→1
May 15, 2024
Merger
5→1
KeyAI